Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 23847922)

1.

[Breast cancer drug resistance induced by the interactions between VEGF pathways and estrogenic endocrine pathways].

Chen SL, Wang TH.

Sheng Li Ke Xue Jin Zhan. 2013 Apr;44(2):115-20. Review. Chinese. No abstract available.

PMID:
23847922
2.
3.

Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.

Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H.

Cell Growth Differ. 2001 Mar;12(3):129-35.

4.

Molecular mechanisms of hormone resistance of breast cancer.

Scherbakov AM, Krasil'nikov MA, Kushlinskii NE.

Bull Exp Biol Med. 2013 Jul;155(3):384-95.

PMID:
24137610
5.

Sex-steroid regulation of vascular endothelial growth factor in breast cancer.

Hyder SM.

Endocr Relat Cancer. 2006 Sep;13(3):667-87. Review.

6.

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.

Massarweh S, Schiff R.

Clin Cancer Res. 2007 Apr 1;13(7):1950-4. Review.

7.
8.

Regulation of vascular endothelial growth factor expression by estrogens and progestins.

Hyder SM, Huang JC, Nawaz Z, Boettger-Tong H, Mäkelä S, Chiappetta C, Stancel GM.

Environ Health Perspect. 2000 Oct;108 Suppl 5:785-90. Review.

PMID:
11035983
9.
10.

Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.

Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM.

Ann N Y Acad Sci. 2002 Jun;963:104-15.

PMID:
12095935
11.

Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy.

Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM.

Endocr Relat Cancer. 2004 Dec;11(4):623-41. Review.

12.

Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?

Bedard PL, Freedman OC, Howell A, Clemons M.

Breast Cancer Res Treat. 2008 Apr;108(3):307-17. doi: 10.1007/s10549-007-9606-8. Epub 2007 May 22. Review.

PMID:
18351454
13.

Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.

Nicholson RI, McClelland RA, Robertson JF, Gee JM.

Endocr Relat Cancer. 1999 Sep;6(3):373-87. Review.

14.

Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.

Roy V, Perez EA.

Breast Cancer Res Treat. 2009 Jul;116(1):31-8. doi: 10.1007/s10549-008-0268-y. Epub 2008 Dec 20. Review.

PMID:
19101790
15.
16.

Targeting tumor angiogenesis.

Gaur P, Bose D, Samuel S, Ellis LM.

Semin Oncol. 2009 Apr;36(2 Suppl 1):S12-9. doi: 10.1053/j.seminoncol.2009.02.002.

PMID:
19393831
17.

Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.

Tie J, Desai J.

Crit Rev Oncog. 2012;17(1):51-67. Review.

PMID:
22471664
18.

Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.

Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK.

Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:10-20. Review.

PMID:
16273359
19.

Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism.

Buteau-Lozano H, Velasco G, Cristofari M, Balaguer P, Perrot-Applanat M.

J Endocrinol. 2008 Feb;196(2):399-412. doi: 10.1677/JOE-07-0198.

20.

Mechanisms of resistance to hormonal treatment in breast cancer.

Eroles P, Bosch A, Bermejo B, Lluch A.

Clin Transl Oncol. 2010 Apr;12(4):246-52. doi: 10.1007/s12094-010-0500-1. Review.

PMID:
20462833
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk